Cold Spring Harbor, NY — Cold Spring Harbor Laboratory (CSHL) is pleased to report that the U.S. Patent & Trademark Office has denied all 4 petitions filed by Benitec Biopharma Ltd seeking to invalidate CSHL’s patents directed to shRNA.
“We are happy with the result, but are not surprised.” said Dr. Bruce Stillman, President and Chief Executive Officer of the Laboratory. “CSHL vigorously defended its patents against these challenges. Dr. Gregory Hannon and his team, though their pioneering work at CSHL, are recognized around the world for having developed shRNA to knock down gene expression in mammalian cells. Benitec’s claims to the contrary were rejected by the Patent Office. We look forward to enhancing our shRNA licensing program with this well-deserved confirmation by the Patent Office of CSHL’s key role in this technology.”
Written by: Communications Department | publicaffairs@cshl.edu | 516-367-8455